前列腺床照射的替代放射肿瘤学方法(PAROS):前瞻性多中心随机III期试验
PAROS是一项前瞻性、多中心、随机III期试验,纳入根治性前列腺切除术后局限性前列腺癌患者,随机分为常规分割光子放疗(70.0/2.0 Gy)、大分割光子放疗(57.0/3.0 Gy)或大分割质子放疗(57.0/3.0 Gy RBE),计划入组897例。主要目标是证明质子治疗相比光子放疗在12周时EORTC QLQ-PR25肠道评分较基线的改善,次要目标包括大分割放疗对比常规分割放疗在生化无进展生存、总生存、生活质量和毒性方面的非劣效性。
要点
- PAROS试验比较前列腺切除术后前列腺床大分割光子、大分割质子与常规分割光子放疗。
- 主要终点为质子治疗对比光子放疗12周时EORTC QLQ-PR25肠道评分较基线的改善。
- 次要终点包括大分割放疗对比常规分割放疗的bPFS、OS、生活质量和毒性的非劣效性。
核心结论
- 该试验旨在评估前列腺床大分割光子和质子放疗的作用,以期对接受手术的前列腺癌患者的未来管理产生重大影响。
研究设计与样本
- 前瞻性、多中心、随机III期试验,纳入根治性前列腺切除术后局限性前列腺癌男性患者。
- 患者随机分为常规分割光子放疗(70.0/2.0 Gy)、大分割光子放疗(57.0/3.0 Gy)或大分割质子放疗(57.0/3.0 Gy RBE)。
- 采用区组随机化,按Gleason评分(≤7 vs. >7)和治疗指征(辅助 vs. 挽救)分层。
- 计划入组897例患者。
关键数值与推荐
- 主要目标:证明质子治疗相比光子放疗在12周时EORTC QLQ-PR25肠道评分较基线的改善。
- 次要目标:大分割放疗对比常规分割放疗在生化无进展生存(bPFS)、总生存(OS)、生活质量和毒性方面的非劣效性。
临床怎么用
- 该试验结果将为前列腺切除术后患者选择大分割光子或质子放疗提供高级别证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with treatment-naïve carcinoma of the prostate, hypofractionated irradiation becomes more and more popular. Due to the low α/β value of prostate cancer, increased single dose leading to a shortened treatment period seems to be safe and feasible. However, reliable data is lacking for post-prostatectomy patients so far. Further, the role of proton therapy is still under debate. Two prospective phase II trials with both, hypofractionated photon and proton therapy, provided promising results. METHODS/ DESIGN: The PAROS trial is a prospective, multicenter and randomized phase III trial for men with localized prostate carcinoma after surgery. Post-prostatectomy patients will be randomized to either normofractionated radiotherapy (nRT) with photons (70.0/ 2.0 Gy), or hypofractionated radiotherapy (hRT) with photons (57.0/ 3.0 Gy) or hRT with protons (57.0/ 3.0 Gy relative biological effectiveness [RBE]). Block randomization is stratified by Gleason Score (≤ 7 vs. > 7) and treatment indication (adjuvant vs. salvage). The trial is planned to enroll 897 patients. The primary objective is to show an improvement in the bowel-score according to EORTC QLQ-PR25 after proton therapy compared to photon irradiation (week 12 vs. baseline). Secondary aims are non-inferiority of hRT compared to nRT with regard to biochemical progression-free survival (bPFS), overall survival (OS), quality of life and toxicity. DISCUSSION: The present study aims to evaluate the role of hypofractionated radiotherapy to the prostate bed with photons and protons leading to significant impact on future management of operated men with prostate cancer. TRIAL REGISTRATION: Deutsches Register klinischer Studien: DRKS00015231 ; registered 27 September 2018.
引用
- Koerber SA, Katayama S, Sander A, et al. Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial. Radiat Oncol. 2019. PMID: 31291969. doi:10.1186/s13014-019-1325-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。